Welcome to our dedicated page for Bicara Therapeutics news (Ticker: BCAX), a resource for investors and traders seeking the latest updates and insights on Bicara Therapeutics stock.
Bicara Therapeutics Inc. reports clinical and corporate developments as a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody combining an EGFR-directed monoclonal antibody with a domain that binds human TGF-beta, with company updates focused on first-line recurrent or metastatic HPV-negative HNSCC and the FORTIFI-HN01 pivotal trial.
Recurring news also includes quarterly financial results, business updates, public equity financing, common stock and pre-funded warrant offerings, Nasdaq inducement grants, and executive appointments tied to clinical development, medical affairs and commercial readiness.
Bicara Therapeutics (Nasdaq:BCAX) reported three-year follow-up from a Phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma.
At 1500mg weekly, estimated three-year overall survival was 31%, with high complete and deep response rates and a generally well-tolerated safety profile, supporting the ongoing FORTIFI-HN01 pivotal program.
Bicara Therapeutics (Nasdaq: BCAX) granted an inducement stock option to new Chief Commercial Officer Christopher Sarchi under its 2026 Inducement Plan, effective May 8, 2026.
The option covers 282,240 shares at an exercise price of $22.58, vesting over four-plus years under Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics (Nasdaq: BCAX) reported Q1 2026 results and a business update focused on ficerafusp alfa in HPV-negative head and neck cancer.
FORTIFI-HN01 enrollment is on track for an interim analysis in mid-2027. A new randomized loading/maintenance study is expected to start in Q3 2026. Long-term Phase 1b data will be presented at ASCO 2026, and additional mCRC data are planned for 2H 2026.
Cash, cash equivalents and marketable securities were $539.8 million, boosted by $161.8 million in net public offering proceeds, funding operations into 1H 2029. Q1 R&D was $47.5 million, G&A $12.7 million, and net loss $56.2 million, all higher year over year. Leadership changes include promoting Bill Schelman to Chief Medical Officer and appointing Chris Sarchi as Chief Commercial Officer.
Bicara Therapeutics (Nasdaq: BCAX) will report first quarter 2026 financial results and business updates before the market opens on May 11, 2026. A conference call will follow at 8:30 a.m. ET, with a live webcast and a replay available for 30 days.
Registration is required for dial-in details and a unique PIN; the webcast is available in the Investors & Events section on the company website.
Bicara Therapeutics (Nasdaq: BCAX) awarded an inducement non-qualified stock option on April 1, 2026, to a new employee for 44,175 shares at an exercise price of $20.50, equal to the Nasdaq closing price on April 1, 2026.
The option vests 25% after one year, then in 12 equal quarterly installments, and was granted under Bicara’s 2026 Inducement Plan adopted in January 2026 and approved by an independent compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics (Nasdaq: BCAX) reported Q4 and full-year 2025 results and business updates on March 30, 2026. The company selected 1500mg ficerafusp alfa for Phase 3 FORTIFI-HN01, initiated Phase 3, and expects an interim analysis mid-2027. Bicara announced a less‑frequent loading/Q3W maintenance schedule and reported a cash position of $414.8M as of Dec 31, 2025, with an additional $161.8M raised in Q1 2026 to fund operations into H1 2029.
R&D and G&A expenses and net loss widened in 2025 versus 2024 amid pivotal trial investments.
Bicara Therapeutics (Nasdaq: BCAX) will report fourth quarter and full year 2025 financial results and provide business updates on March 30, 2026 before market open. A conference call and live webcast will occur at 8:30 a.m. ET, with registration, dial-in PINs, and a 30-day replay available.
Bicara Therapeutics (Nasdaq: BCAX) awarded an inducement non-qualified stock option on March 2, 2026 to a new employee for 115,000 shares at an exercise price of $17.59, equal to the Nasdaq closing price that day.
The award vests 25% after one year, then in 12 equal quarterly installments, was granted under Bicara’s 2026 Inducement Plan (adopted January 2026) and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics (Nasdaq: BCAX) closed an oversubscribed underwritten public offering on Feb 26, 2026, selling 8,581,250 shares and offering pre-funded warrants for 2,200,000 shares.
The underwriters fully exercised a 1,406,250-share option. Public prices were $16.00 per share and $15.9999 per pre-funded warrant, generating approximately $172.5 million gross proceeds before fees. Bicara plans to use net proceeds for regulatory filing and potential U.S. commercial launch of ficerafusp alfa, development in 1L R/M HPV-negative HNSCC, manufacturing, indication expansion signal-finding, and general corporate purposes.
Bicara Therapeutics (Nasdaq: BCAX) priced an underwritten public offering of 7,175,000 common shares at $16.00 per share and 2,200,000 pre-funded warrants at $15.9999 each, for gross proceeds of approximately $150 million. Closing is expected on or about February 26, 2026.
The company granted a 30-day underwriter option for 1,406,250 additional shares. Net proceeds will fund regulatory and commercial preparation for ficerafusp alfa, development in 1L R/M HPV-negative HNSCC, manufacturing, indication expansion signal-finding, and general corporate purposes.